1454885-45-0
1454885-45-0 structure
- Name: SP-8356
- Chemical Name: SP-8356
- CAS Number: 1454885-45-0
- Molecular Formula: C18H20O4
- Molecular Weight: 300.35
- Catalog: Signaling Pathways Apoptosis Apoptosis
- Create Date: 2020-06-01 17:45:49
- Modify Date: 2025-09-12 17:51:44
-
SP-8356, an anti-inflammatory synthetic verbenone derivative, is a potent, orally active cluster of differentiation 147 (CD147) inhibitor. SP-8356 inhibits CD147-cyclophilin A (CypA) interaction and reduces MMP-9 activity. SP-8356 exerts anti-breast cancer effects by inhibiting NF-κB signaling. Anti-atherosclerotic effects[1][2][3].
| Name | SP-8356 |
|---|
| Description | SP-8356, an anti-inflammatory synthetic verbenone derivative, is a potent, orally active cluster of differentiation 147 (CD147) inhibitor. SP-8356 inhibits CD147-cyclophilin A (CypA) interaction and reduces MMP-9 activity. SP-8356 exerts anti-breast cancer effects by inhibiting NF-κB signaling. Anti-atherosclerotic effects[1][2][3]. |
|---|---|
| Related Catalog | |
| In Vitro | SP-8356 (5-10 μM; 48 hours) inhibits growth of various types of breast cancer cell lines in a time- and dose-dependent manner[1]. SP-8356 (10 μM; 48 hours) increases percentage of MDA-MB231 cells in S phase and decreases casapas-3 and cleaved PARP[1]. Cell Proliferation Assay[1] Cell Line: MDA-MB231, MDA-MB453, 4T1, and MCF-7 cells Concentration: 5, 10 μM Incubation Time: 48 hours Result: Inhibited growth of various types of breast cancer cell lines in a time- and dose-dependent manner. Cell Cycle Analysis[1] Cell Line: MDA-MB231 cells Concentration: 1, 5, 10 μM Incubation Time: 48 hours Result: Increased percentage of MDA-MB231 cells in S phase at 10 μM. Western Blot Analysis[1] Cell Line: MDA-MB231 cells Concentration: 10 μM Incubation Time: 48 hours Result: Decrease of casapas-3 and cleaved PARP were observed. |
| In Vivo | SP-8356 (10 mg/kg; i.p.; every three days until the 42nd day) inhibits tumor growth in a xenograft mouse model[1]. SP-8356 (50 mg/kg; p.o.; daily one day after carotid artery ligation for three weeks) prevents the formation of plaque and attenuates its vulnerability[2]. Animal Model: Five-week-old female NOD/SCID mice (MDA-MB231 xenografts)[1] Dosage: 10 mg/kg Administration: I.p.; every three days until the 42nd day Result: The tumor volumes of mice were significantly lower. Animal Model: Male ApoE KO mice (7 weeks old, 20 g body weight)[2] Dosage: 50 mg/kg Administration: P.o.; daily one day after carotid artery ligation for three weeks Result: Induced a significant reduction in plaque size and plaque/media ratiowith decreased lipid and necrotic core areas. |
| References |
| Molecular Formula | C18H20O4 |
|---|---|
| Molecular Weight | 300.35 |